How does Retatrutide work?
Triple agonist, GLP-1, GIP, and glucagon receptors all activated by one molecule. The glucagon arm adds metabolic-rate elevation (mild thermogenesis) on top of the appetite suppression, driving the largest trial weight-loss effect to date. In plain terms, Retatrutide is triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- People plateaued on Tirzepatide
- Users targeting >15% body weight loss
- Metabolic-syndrome adults under provider guidance
References
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2) — Jastreboff AM et al., NEJM, 2023
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA — Rosenstock et al., Lancet, 2023
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Sanyal et al., Nature Medicine, 2024
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Retatrutide
Last updated 2026-06-06.